Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alimta in previously treated malignant pleural mesothelioma
NCT00190762Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2001
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pemetrexed in malignant pleural mesothelioma (MPM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall Survival. Started Oct 2001; status: completed.
02
Drugs
pemetrexed
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT00190762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00190762.